Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Celldex Therapeutics (NasdaqCM:CLDX) with a Buy ...

Standard Chartered Bank’s recent Market Outlook event has received resounding praise from clients, with many hailing it as ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

MaxCyte (MXCT) announced they are entering into a strategic platform license with TG Therapeutics (TGTX). Under the terms of the agreement, TG ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Travere Therapeutics aims to seek traditional approval based on data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI, with submission expected by the end of the first quarter of 2025. The ...

Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders –– Capital raising was strongly supported by domestic and ...

Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...